B. Braun Medical Care AG Nephrology and Dialysis centers

FAQs on H.E.L.P. apheresis

We have set up a website to serve as the initial point of contact, which features information and a questionnaire that the potential patient can use to provide us with some basic details to start with. If a patient meets the requirements (these are clarified using a questionnaire), they are first placed on a waiting list. As soon as places are available, a detailed patient interview is conducted and the requisite laboratory tests (assessment) carried out. The aim here is, among other things, to identify the severity of the patient’s symptoms and clarify whether the prerequisites for treatment using H.E.L.P. apheresis – in terms of the intended purpose of the Plasmat Futura device – are fulfilled.

The costs of around CHF 2,000 per treatment are currently borne by the patient. Of course, the patient can apply to their health insurance for coverage of the costs.

H.E.L.P. apheresis is recognized and the cost rates regulated in Switzerland for patients with homozygous familial hypercholesterolemia. For all other indications for H.E.L.P. apheresis, there are currently no fixed rates and cover by the health insurance fund depends on each individual case. Of course, we support the patient with applying to their health insurance company.

The symptoms of Long Covid vary greatly. Any organ system can be affected. Treatments carried out to date indicate that many of these symptoms can be successfully treated by improving microcirculation.

H.E.L.P. apheresis is generally very well tolerated and has few complications. But, as with any treatment, it does have risks and side effects. However, these are very rare and are easily treated. For example, the patient may have hematomas at the injection sites, a short-term vasovagal reaction (passing out) or temporary fatigue.

Here you can find the publication by Dr. Beate Jäger et al.: To the publication

Website in deutsch